Core 2 GlcNAc-T inhibitors

Details Core 2 GlcNAc-T inhibitors Core 2 GlcNAc-T inhibitors

2011-03-15

2011-03-15

Lewis, Patrick T (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S025000, C514S054000, C514S062000

Reexamination Certificate

active

07906493

ABSTRACT:
Method of treating conditions associated with raised activity of core 2 GlcNAc-T by administering an inhibitor of UDP-GlcNAc:Galβ1,3GalNAc-R (GlcNAc to GalNAc) β1,6-N-acetylglucosaminyl transferase (core 2 β1,6 N-acetylaminotransferase, core 2 GlcNAc-T-EC 2.4.1.102). Diseases associated with raised activity of core 2 GlcNAc-T include inflammatory diseases, atherosclerosis, diabetic cardiomyopathy, cancers, including treatment or prevention of metastasis, or diabetic retinopathy.

REFERENCES:
patent: 4602003 (1986-07-01), Malinow
patent: 5104856 (1992-04-01), Esko et al.
patent: 5360733 (1994-11-01), Fukuda et al.
patent: 5461143 (1995-10-01), Wong et al.
patent: 5470879 (1995-11-01), Sauvaire et al.
patent: 5486510 (1996-01-01), Bouic et al.
patent: 5589182 (1996-12-01), Tashiro et al.
patent: 5624832 (1997-04-01), Fukuda et al.
patent: 5658778 (1997-08-01), Fukuda et al.
patent: 5684134 (1997-11-01), Fukuda et al.
patent: 5827884 (1998-10-01), Obagi
patent: 5843707 (1998-12-01), Larsen et al.
patent: 5880091 (1999-03-01), Cummings et al.
patent: 5886029 (1999-03-01), Dhaliwal
patent: 5952393 (1999-09-01), Sorkin, Jr.
patent: 5958770 (1999-09-01), Cham et al.
patent: 5965449 (1999-10-01), Novak
patent: 5985936 (1999-11-01), Novak
patent: 5997877 (1999-12-01), Chang
patent: 6042834 (2000-03-01), Baraka
patent: 6087353 (2000-07-01), Stewart et al.
patent: 6131578 (2000-10-01), King et al.
patent: 6197832 (2001-03-01), Sorkin, Jr.
patent: 6294157 (2001-09-01), Rubinstenn et al.
patent: 6346267 (2002-02-01), Fry et al.
patent: 6383514 (2002-05-01), Weitkemper et al.
patent: 6407085 (2002-06-01), Kief
patent: 6451355 (2002-09-01), Reisner
patent: 6593301 (2003-07-01), Ma et al.
patent: 6635461 (2003-10-01), Schwientek et al.
patent: 6787151 (2004-09-01), Meijer et al.
patent: 6933291 (2005-08-01), Qi et al.
patent: 6998501 (2006-02-01), Wright et al.
patent: 2002/0016314 (2002-02-01), Schersi
patent: 2002/0018811 (2002-02-01), Penteado et al.
patent: 2002/0098563 (2002-07-01), Korczak et al.
patent: 2002/0107292 (2002-08-01), Bortlik et al.
patent: 2002/0156051 (2002-10-01), Kutney et al.
patent: 2002/0183294 (2002-12-01), Barraclough et al.
patent: 2002/0193317 (2002-12-01), Xia et al.
patent: 2003/0004147 (2003-01-01), Barraclough et al.
patent: 2003/0096316 (2003-05-01), Wester
patent: 2003/0148962 (2003-08-01), Guan et al.
patent: 2004/0033521 (2004-02-01), Korczak et al.
patent: 2004/0038923 (2004-02-01), Marth et al.
patent: 2004/0049352 (2004-03-01), Andre et al.
patent: 2004/0203111 (2004-10-01), Schwientek et al.
patent: 2004/0220115 (2004-11-01), Cham
patent: 2004/0249138 (2004-12-01), Lawson
patent: 2006/0052351 (2006-03-01), Platt et al.
patent: 2007/0254847 (2007-11-01), Liu et al.
patent: 2008/0318875 (2008-12-01), Chibber
patent: 2 186987 (1998-04-01), None
patent: 2186987 (1998-04-01), None
patent: 2 335 436 (2001-08-01), None
patent: 1237583 (1999-12-01), None
patent: 1243129 (2000-02-01), None
patent: 1361111 (2000-12-01), None
patent: 1361111 (2002-07-01), None
patent: 00135190.7 (2005-01-01), None
patent: 4303214 (1994-11-01), None
patent: 0 251 197 (1988-01-01), None
patent: 0 251 197 (1988-01-01), None
patent: 0 251 197 (1988-01-01), None
patent: 1 316 608 (2003-06-01), None
patent: 0 850 243 (2003-10-01), None
patent: 1 800 685 (2007-06-01), None
patent: 03271224 (1991-03-01), None
patent: 2004-143126 (2004-05-01), None
patent: 2 027 434 (1995-01-01), None
patent: 2027434 (1995-01-01), None
patent: 833254 (1981-05-01), None
patent: WO 95/17182 (1995-06-01), None
patent: WO 95/21199 (1995-08-01), None
patent: WO 95/35294 (1995-12-01), None
patent: WO 97/06176 (1997-02-01), None
patent: WO 97/47298 (1997-12-01), None
patent: WO 98/06405 (1998-02-01), None
patent: 98/14459 (1998-04-01), None
patent: WO 98/33494 (1998-08-01), None
patent: WO 98/33494 (1998-08-01), None
patent: WO 99/25197 (1999-05-01), None
patent: WO 99/25197 (1999-05-01), None
patent: WO 99/39715 (1999-08-01), None
patent: WO 99/53925 (1999-10-01), None
patent: WO 00/31109 (2000-06-01), None
patent: WO 00/31109 (2000-06-01), None
patent: WO 00/52029 (2000-09-01), None
patent: WO 00/61153 (2000-10-01), None
patent: WO 00/78789 (2000-12-01), None
patent: WO 01/32679 (2001-05-01), None
patent: 01/58932 (2001-08-01), None
patent: WO 01/83717 (2001-11-01), None
patent: WO01/87548 (2001-11-01), None
patent: WO 02/03996 (2002-01-01), None
patent: WO 02/24212 (2002-03-01), None
patent: WO 02/069980 (2002-09-01), None
patent: WO 02/087548 (2002-11-01), None
patent: 03/043433 (2003-05-01), None
patent: 03/066679 (2003-08-01), None
patent: WO 03/070261 (2003-08-01), None
patent: WO 03/075931 (2003-09-01), None
patent: 03/092394 (2003-11-01), None
patent: WO 2004/002497 (2004-01-01), None
patent: WO 2004/019960 (2004-03-01), None
patent: WO 2004/029068 (2004-04-01), None
patent: WO 2004/048938 (2004-06-01), None
patent: WO 2004/062675 (2004-07-01), None
patent: WO 2004/064852 (2004-08-01), None
patent: 2004/074461 (2004-09-01), None
patent: WO 2004/093662 (2004-11-01), None
patent: WO 2004/111196 (2004-12-01), None
patent: WO 2005/060977 (2005-07-01), None
patent: WO 2005/084323 (2005-09-01), None
patent: WO 2005/120535 (2005-12-01), None
patent: 2006/034655 (2006-04-01), None
patent: WO 2006/034655 (2006-04-01), None
patent: WO 2006/034655 (2006-06-01), None
Mimaki et al. Phytochemistry (1996), vol. 42, pp. 1065-1070.
Matsuda et al. Bioorg. Med. Chem. Lett. (2003), vol. 13, pp. 1101-1106.
Friedman et al. Food and Chemical Toxicology (2003), vol. 41, pp. 61-71.
Rita Aquino et al, “Furostanol Oligosides from Tamus Communis”, Journal of Natural Products vol. 49, No. 6, pp. 1096-1101, Nov.-Dec. 1986.
Jean-Guy Bienvenu et al, “Recombinant Soluble P-Selectin Glycoprotein Ligan-1-Ig Reduces Restenosis through Inhibition of Platelet-Neutrophil Adhesion after Double Angioplasty in Swine”,Circulation. 27;103(8):1128-34 (2001).
Chen C. et al,Yunnan Zhiwu Yanjiu, 9(4), 495-502 (1987).
Chow F. et al., “Macrophages in streptozotocin-induced diabetic nephropathy: potenial role in renal fibrosis” Nephrol Dial Transplant.19(12):2987-96 (2004).
Dang B et al “Increased PSGL-1 expression on granulocytes from allergic-asthmatic subjects results in enhanced leukocyte recruitment under flow conditions”, Journal of Leukocyte Biology, vol. 72,(4), pp. 702-710.
Dedrick R.L. et al , “Adhesition molecules as therapeutic targets for autoimmune diseases and transplant rejection”.
Fujita S. et al , “Dammarane Glycosides from Aerial parts of Neoalsomitra Integrifoliola”,Phytochemistry, 38(2), 465-72 (1995).
Guofeng Gu, et al , “Facile Synthesis of Saponins Containing 2,3-Branched Oligosaccharides by Using Partially Protecgted Glycosyl Donors”, J. Org. Chem 2004, 69, 5497-5500.
Haladova M. et al., “Steroids saponins from the petals ofLilium candidumL.”,Pharmazie, 54(2), 159-160 (1999).
Hansen A. et al., “Evaluation of Cardioprotective Effects of Recombinant Soluble P-Selectin Glycoprotein Ligan-Immunoglobulin in Myocardial Ischemia-Reperfusion Injury by Real-Time Myocardial Contrast Echocardiography”J Am Coll Cardiol. 18;44(4):887-91 (2004).
Hans-Peter Hartung et al, “Circulating Adhesion Molecules and Tumor Necrosis Factor Receptor in Multiple Sclerosis: Correlation with Magnetic Resonance Imaging” Ann Neurol 1995; 38(2), 186-193.
Hickey M. et al., “Leukocyte-Endothelial Cell Interactions are enhanced in Dermal Postcapillary Venules of MRL/fas1pr(Lupus-Prone) Mice: Roles of P- and E-Selectin1”J Immunol. 168(9):4728-36 (2002.
Haworth and Hirst, XXII—The Constitution of the Disaccharides. Part V, Vellobiose (Cellose)J. Chem. Soc. 119, 193 (1921).
Ke Hu et al, “Methyl protogracillin(NSC-698792): the spectrum of cytotoxicity against 60 human cancer cell lines in the National Cancer Institute;s anticancer drug screen panel”, Anti-cancer Drugs 2001, 12, pp. 541-547.
Ke Hu et al “The Cytotoxity ofMethyl Protoneogracillin(NSC-698793) and Gracillin

Affiliated with

Also associated with

Rating

Core 2 GlcNAc-T inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Core 2 GlcNAc-T inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Core 2 GlcNAc-T inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2680301